logo-loader

Redx Pharma confirms start of phase I study of lead drug RXC004

Published: 13:13 13 Jun 2019 BST

Redx Pharma Plc's (LON:REDX) Lisa Anson speaks to Proactive London's Andrew Scott following the release of their interims to the end of March 2019.

Initial results from a phase I study of its lead drug, RXC004, a porcupine inhibitor aimed at treating cancer driven by the Wnt pathway, are expected in the second half of the year, with the full read-out expected in early 2020.

Redx has also secured short-term funding with a loan of up to £2.5mln and is in talks to find a longer-term financing solution.

Redx Pharma achieves milestone with dosing of first participant in Phase 1...

  Redx Pharma PLC (AIM:REDX) CEO Lisa Anson discusses the enrollment of the first participant in its RXC008 Phase 1 clinical trial in an interview with Proactive's Stephen Gunnion. RXC008 is a 'first-in-class' ROCK inhibitor, designed to be gut-restricted, targeting fibrostenotic Crohn's...

2 weeks, 6 days ago